Corporate Negligence Case Study: Alcon Laboratories Inc. & Its Impact on Consumer Health
TLDR; A Summary of the Allegations: A class-action lawsuit alleges that Alcon Laboratories Inc. sold Systane brand eye drops labeled as “STERILE” despite them being contaminated with fungus. The complaint, filed in federal court, claims the company knew its product was adulterated but continued to market it as safe, leading to a nationwide recall only after a consumer discovered foreign material in a sealed vial. The plaintiff claims she suffered eye irritation and swelling, arguing that Alcon’s pursuit of profit knowingly put consumers at risk of vision-threatening infections.
Continue reading to understand the full scope of the allegations and how this case highlights critical failures in corporate accountability and consumer protection.
The Betrayal in a Bottle: When “Sterile” Is a Lie
A promise of relief, sealed in a small plastic vial. For the millions of Americans who suffer from dry, irritated eyes, a product labeled “STERILE” is not a marketing gimmick; it is a fundamental requirement for safety.
Yet, according to a federal lawsuit, Alcon Laboratories Inc., a major player in the global eye care market, betrayed that basic trust by allegedly selling its Systane Lubricant Eye Drops while they were contaminated with fungus.
This is a story of corporate negligence, where the foundational claim of product safety was seemingly abandoned in the pursuit of profit.
A class-action complaint filed on February 20, 2025, paints a damning picture of a company that marketed and sold a product for sensitive eyes that allegedly posed a risk of severe infection, all while reassuring customers with the word “STERILE” emblazoned on its packaging. The case of Kathy Even v. Alcon Laboratories Inc. serves as a crucial reminder of the human cost when corporate oversight fails and regulatory systems are pushed to their limits.
Inside the Allegations: A Contaminated Product and a Consumer Left in the Dark
The core of the lawsuit is a straightforward, yet deeply disturbing, accusation: the eye drops sold by Alcon were not– in fact– sterile.
The plaintiff, Kathy Even of Aurora, Colorado, purchased Systane Lubricant Eye Drops Ultra PF, a preservative-free formula marketed for sensitive eyes. She used the product as directed, trusting the packaging’s explicit promise of sterility, only to suffer from red eyes, ocular swelling, itching, and discharge, which required a visit to an eye doctor.
The lawsuit alleges that Alcon acknowledged the product was adulterated with fungus but refused to specify the type. The company’s own recall notice, issued on December 21, 2024, confirms the basis for this fear. It states that after a consumer complaint about “foreign material observed inside a sealed single use vial,” Alcon’s own evaluation determined the material to be “fungal in nature.”
Timeline of an Alleged Public Health Failure
| Date | Event |
| Undisclosed | Plaintiff Kathy Even purchases and uses Systane Lubricant Eye Drops Ultra PF, allegedly suffering personal injury as a result. |
| Dec. 21, 2024 | Alcon Laboratories Inc. issues a voluntary recall for one lot of the eye drops after a consumer complaint leads to the discovery of fungal contamination in a sealed vial. The company’s risk statement acknowledges that fungal contamination can cause “vision-threatening” infections. |
| Dec. 23, 2024 | The U.S. Food and Drug Administration (FDA) publishes Alcon’s recall announcement. |
| Dec. 24, 2024 | Plaintiff Kathy Even receives a product recall notice that “urges” consumers to stop using the product immediately but allegedly does not offer a direct refund. |
| Feb. 20, 2025 | A class-action lawsuit is filed against Alcon in the U.S. District Court for the District of Colorado, accusing the company of negligence, breach of warranty, and violations of consumer protection laws. |
The complaint argues that the presence of this pathogen poses a significant health risk. Even more troubling is the company’s own admission in its recall notice that such contamination could lead to “vision-threatening” infections and, in rare cases, could be “life-threatening in immunocompromised patients.” Despite this grave risk, the plaintiff alleges she was never offered a refund and was left with a worthless, and potentially dangerous, product.
Regulatory Capture & Loopholes in Neoliberal Capitalism
This case is a textbook example of how the modern economic landscape, shaped by neoliberal ideology, often relies on corporate self-policing, a system that can spectacularly fail consumers. The recall was not initiated by a proactive regulatory inspection but was a reaction to a consumer complaint. While the FDA published the recall notice, the initial discovery and action came from outside the regulatory apparatus designed to prevent such incidents.
The lawsuit points to a cascade of potential failures in Alcon’s manufacturing and quality control processes—failures that should be caught by robust internal and external oversight. These include a compromised sterile manufacturing environment, inadequate sterilization of raw ingredients, faulty packaging seals, and improper storage conditions.
Under a system of deregulation, companies are often left to monitor themselves, creating a direct conflict between the expensive, time-consuming work of ensuring safety and the relentless pressure to maximize profits. The “STERILE” label, in this context, becomes not a guarantee but a calculated risk, wagered against the odds of getting caught.
Profit-Maximization at All Costs: A Corporate Ethics Failure
A corporation’s primary legal mandate is to generate value for its shareholders. However, late-stage capitalism often sees this mandate pursued with a ferocity that sidelines public health and ethical considerations.
The lawsuit against Alcon alleges that the company engaged in false and misleading advertising, unjustly enriched itself, and failed to adhere to good manufacturing practices.
By allegedly selling a contaminated product, Alcon received money for a product that was not what it claimed to be.
The plaintiff argues she paid a “price premium” for the trusted “Alcon Systane” brand name—a premium paid for a promise of quality and safety that was allegedly broken. This is the essence of profit-maximization at its most cynical: leveraging a trusted brand to sell a product that fails to meet its most basic standard, thereby converting public trust directly into revenue while externalizing the health risks onto the consumer.
The Economic and Public Health Fallout
The consequences of this alleged failure extend beyond a single person’s irritated eyes. The lawsuit seeks to represent a class of “thousands of purchasers” in Colorado who all paid for a product that was, at best, useless and, at worst, dangerous.
The economic damage is clear: consumers spent money on a product they would not have purchased had they known the truth. They are now faced with the burden of seeking refunds or replacements, a process the lawsuit suggests was not made easy.
The public health risks are far more severe. The eye is a uniquely vulnerable entry point for pathogens. An infection that begins in the eye can have devastating consequences. The recall notice itself confirms this, speaking of “vision-threatening” outcomes.
The victim here fears future injury from having used the adulterated product for months. This fear, shared by every consumer of the recalled lot, is a direct consequence of a corporate entity’s alleged failure to ensure its product was safe. The burden of this anxiety, and the potential for real physical harm, falls squarely on the public.
The PR Machine and Legal Minimalism
In the face of a public health crisis, corporate communication is key.
Alcon’s recall notice is an exercise in legal minimalism. It acknowledges the fungal contamination and the potential risks but also notes that, “To date, Alcon Laboratories has not received any reports of adverse events related to this recall.” This statement, while factually accurate at the time, can serve to downplay the severity of the situation and may discourage consumers from connecting their own symptoms to the product.
Furthermore, the plaintiff alleges the recall notice she received did not directly offer a refund, placing the onus on the consumer to navigate the process of seeking restitution. This is a common tactic in a corporate playbook designed to limit financial liability.
By making the process of redress even slightly more difficult, companies can significantly reduce the number of people who actually get their money back, effectively retaining profits from a product now known to be defective.
Corporate Accountability Fails the Public
The lawsuit’s demands go beyond simple refunds. The lawsuit’s plaintiff asks the court to enjoin Alcon from selling the product and from implying it is safe, to order a corrective advertising campaign, and to force the company to disgorge its “ill-gotten benefits.” This is a plea for meaningful corporate accountability.
In our current system, corporations are often able to settle such lawsuits with financial payouts but without any admission of wrongdoing.
Executives rarely face personal liability, and the fines can amount to little more than a cost of doing business. The lawsuit against Alcon is a challenge to that status quo. It argues that retaining money from the sale of a defective and dangerous product is “inequitable” and constitutes unjust enrichment. Whether the legal system will force a genuine reckoning remains to be seen.
Frivolous or Serious Lawsuit?
Based on the detailed allegations presented in the legal complaint, this lawsuit appears to be a serious and legitimate legal grievance. The central claim rests on the defendant’s own admission in its recall notice: a product sold as “STERILE” was found to contain fungus.
The case is not based on subjective disappointment but on a fundamental failure of the product to meet its most critical safety specification—a failure acknowledged by the company itself. The plaintiff alleges both economic injury (paying for a worthless product) and personal, physical injury (eye irritation and swelling).
Supported by the company’s own recall documentation and the explicit “STERILE” promise on the packaging, the lawsuit presents a well-documented challenge to a corporation’s alleged breach of public trust and safety standards. It represents a significant effort to hold a major corporation accountable for the safety of the products it puts on the market.
💡 Explore Corporate Misconduct by Category
Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.
- 💀 Product Safety Violations — When companies risk lives for profit.
- 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
- 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
- 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
- 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.
